THE TLC-NOSF* TECHNOLOGY
Discover the unique mode of action for the UrgoStart treatment range
HOW DOES THE URGOSTART TREATMENT RANGE REDUCE HEALING TIME?
In leg ulcers, diabetic foot ulcers and pressure ulcers two key factors significantly impair wound healing
IMPAIRED BLOOD VESSELS
Excess proteases, called Matrix Metalloproteinases (MMPs), which destroy essential extracellular matrix (ECM) components (1)
An impaired blood vessels network leading to hypoxia and defective micronutrient delivery (2)
UrgoStart treatment is composed of a unique TLC-NOSF* Healing Matrix, which acts locally in the wound, on the 2 key factors significantly impairing wound healing:
INHIBITION OF EXCESS MMPS
Inhibits excess Matrix Metalloproteinases (MMPs) (3)
Promotion of angiogenesis (3,4)
UrgoStart Plus Pad and Border also contain poly-absorbent fibres which bind, trap and retain exudate, slough and debris present in the wound, keeping it clean throughout healing.
The TLC-NOSF Healing Matrix is the technology common to all formats of the range. Therefore regardless of which format is most suitable for your patient, they will benefit from reduced healing time.
*NOSF (Nano OligoSaccharide Factor) = KSOS (potassium sucrose octasulfate)
(1) Lázaro JL, Izzo V, Meaume S, Davies AH, Lobman Rm Uccioli L. Elevated levels or matrix metalloproteinases and chronic wound healing: an updated review of clinical evidence. J Wound Care 2016: 25(5):277-287.
(2) Honnegowda TM, Kumar P, Udupa EG, Kumar S, Kumar U, Rao P. Role of angiogenesis and angiogenic factors in acute and chronic wound healing. Plast Aesthet Res 2015;2:243-9. Role of angiogenesis and angiogenic factors in acute and chronic wound healing. (3) White, R., Cowan, T., Glover, D. Supporting evidence-based practice: review of TLC healing matrix (2nd edition). MA Healthcare Ltd, London, 2015. (4) Edmonds M, Lázaro-Martínez JL, Alfayate-García JM, Martini J, Petit JM, Rayman G, Lobmann R, Uccioli L, Sauvadet A, Bohbot S, Kerihuel JC, Piaggesi A. Sucrose octasulfate dressing versus control dressing in patients with neuroischaemic diabetic foot ulcers (Explorer): an international, multicentre, double-blind, randomised, controlled trial. Lancet Diabetes Endocrinol. 2018 Mar;6(3):186-196.